Focus: Mestag Therapeutics is a UK-based biotech company leveraging fibroblast biology and immunology to discover antibody-based cancer therapies. The company is in early clinical stage with one Phase 1 program targeting solid malignancies.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
High-risk, high-reward opportunity best suited for scientists willing to take equity upside in exchange for clinical and financial uncertainty in a newly-funded startup.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Mestag Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Mestag Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting - Yahoo Finance
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting Yahoo Finance
Eric Topol boards Flagship as advisor—Chutes & Ladders - Fierce Biotech
Eric Topol boards Flagship as advisor—Chutes & Ladders Fierce Biotech
R1 Leads Busy Fundraising Day With $77.5M Series A Raise for Kidney Disease - BioSpace
R1 Leads Busy Fundraising Day With $77.5M Series A Raise for Kidney Disease BioSpace
Mestag Therapeutics: $40 Million Raised To Advance Fibroblast Immunology Cancer Therapies Into Clinic - Pulse 2.0
Mestag Therapeutics: $40 Million Raised To Advance Fibroblast Immunology Cancer Therapies Into Clinic Pulse 2.0
Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic - Yahoo Finance
Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic Yahoo Finance
Mestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinic - European Biotechnology Magazine
Mestag Therapeutics raises $40M and adds two senior biotech executives as lead cancer program nears the clinic European Biotechnology Magazine
Showing 6 of 9 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
SPECT as a translational non-invasive method to assess occupancy of the tissue transglutaminase-2 by zampilimab in the mouse lung.
Using skin biopsies to measure target occupancy of anti-fibrotic molecules: assay development and application for zampilimab in a primate model of chronic kidney disease and in healthy human volunteers.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo